Co-Diagnostics Q4 2023 GAAP EPS $(0.50) Misses $(0.20) Estimate, Sales $3.555M Miss $3.625M Estimate
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics (NASDAQ:CODX) reported Q4 2023 GAAP EPS of $(0.50), missing the $(0.20) estimate, with sales of $3.555M also missing the $3.625M estimate. Despite this, sales increased by 153.75% compared to the same period last year.
March 14, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Co-Diagnostics reported a significant miss in both EPS and sales for Q4 2023, but showed a substantial year-over-year sales increase.
The miss in both EPS and sales estimates is likely to negatively impact investor sentiment in the short term, despite the significant year-over-year sales growth. The magnitude of the miss, especially in EPS, suggests potential underlying issues that could concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100